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Forkhead box P3 (Foxp3) gene is an important means in the Treg cells function, in both 
maintenances of immune tolerance and regulation of response. Epigenetic modifications of the 
foxp3 gene at its regulatory regions control the chromatin accessibility for the transcription factors 
and other transcriptional regulators in order to control Foxp3 expression. In addition, the 
methylation status of CpG islands within the Foxp3 promoter and regulatory elements regulate the 
expression of Foxp3. This study was performed to assess the role of the foxp3 gene in patients 
with Behçet’s syndrome (BS).  
Venous blood samples were collected from all participants and peripheral blood mononuclear 
cells (PBMC) were extracted through Ficoll-Hypaque method. Genomic DNA was randomly 
sheared by sonication and immunoprecipitated with a monoclonal antibody. The status 
methylation of the foxp3 gene was estimated in 108 blood samples of active BS patients and 
healthy individuals (controls); using methylation DNA immunoprecipitation (MeDIP) technique. 
Expression analysis was carried out; using Real-time PCR. 
The expression of foxp3 gene in the patients' group (mean±SD: 1.79±1.12) was significantly 
lower than the healthy group (mean±SD: 2.73±1.33) (p<001). Also, the methylation levels of 
Foxp3 promoter showed that its level in patients (mean±SD: 2.3±1.16) was higher than the 
healthy group (mean±SD: 1.85±0.59). However, this increase was not statistically significant 
(p>0.05). Also, these results indicated that increasing the amount of methylation of the foxp3 gene 
by reducing its expression leads to an increase and intensifying of the disease. 
The decrease in Foxp3 expression is possibly associated with hypermethylation of the gene, 
and it can be considered as a risk factor for BS. Future studies may be needed to identify the 
capability of specific DNA methylation alterations in this syndrome. 
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